Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Bone Regeneration and Membranous Nephropathy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for NELL1 drug discovery and diagnostic development. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NELL1 ECD-Fc / Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified, HEK293 Expressed (Native Glycosylation). |
View NELL1 Products |
| Gene Delivery | NELL1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View NELL1 Products |
| Benchmark Ab | Anti-NELL1 Recombinant positive control for diagnostic assay calibration. |
View NELL1 Products |
| Validator | NELL1 siRNA Set For knockdown verification in cell models. |
View NELL1 Products |
| Related Target A | PLA2R1 Primary biomarker for primary membranous nephropathy (multiplex panel partner). |
View PLA2R1 Products |
| Related Target B | THSD7A Secondary biomarker for membranous nephropathy. |
View THSD7A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Autoantibody Detection | HEK293 Expressed (Native Glycosylation) preserves exact human epitopes. |
| False Positives in Diagnostics | High Purity (>95%) strictly verified by mass spectrometry and SEC-HPLC. |
| Lack of Controls | Recombinant Benchmark Antibodies included for standard curves. |
Live NELL1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The clinical landscape for NELL1 is rapidly bifurcating into two distinct high-value sectors: diagnostic biomarkers for NELL1-associated membranous nephropathy (MN) and therapeutic recombinant proteins for osteogenesis and tissue regeneration. As the understanding of non-PLA2R1 MN expands, NELL1 testing is becoming a standard in nephrology diagnostic panels, driving the demand for structurally pristine antigens.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Diagnostic ELISA/CLIA | Major IVD Companies | Membranous Nephropathy | Autoantibody Detection (Need natively folded, glycosylated ECD) |
| Recombinant Protein | Bone Regeneration Biotechs | Spinal Fusion, Osteoporosis | Receptor Binding Assays (Need Endotoxin <1EU/ug proteins) |
| Gene Therapy | Academic/Early Biotech | Bone Defects | Expression Validation (Need specific benchmark Abs) |